- Home
- SCNI vs SNPX Comparison
SCNI vs SNPX Comparison
Compare SCNI & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- SNPX
- Stock Information
- Founded
- SCNI 2003
- SNPX 2012
- Country
- SCNI Israel
- SNPX United States
- Employees
- SCNI N/A
- SNPX N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- SCNI Health Care
- SNPX Health Care
- Exchange
- SCNI Nasdaq
- SNPX Nasdaq
- Market Cap
- SCNI 3.5M
- SNPX 3.7M
- IPO Year
- SCNI N/A
- SNPX N/A
- Fundamental
- Price
- SCNI $3.48
- SNPX $2.69
- Analyst Decision
- SCNI
- SNPX Strong Buy
- Analyst Count
- SCNI 0
- SNPX 1
- Target Price
- SCNI N/A
- SNPX $14.00
- AVG Volume (30 Days)
- SCNI 13.0K
- SNPX 13.5K
- Earning Date
- SCNI 11-22-2024
- SNPX 11-12-2024
- Dividend Yield
- SCNI N/A
- SNPX N/A
- EPS Growth
- SCNI N/A
- SNPX N/A
- EPS
- SCNI 8.20
- SNPX N/A
- Revenue
- SCNI $452,000.00
- SNPX N/A
- Revenue This Year
- SCNI N/A
- SNPX N/A
- Revenue Next Year
- SCNI N/A
- SNPX N/A
- P/E Ratio
- SCNI $0.42
- SNPX N/A
- Revenue Growth
- SCNI N/A
- SNPX N/A
- 52 Week Low
- SCNI $2.23
- SNPX $2.32
- 52 Week High
- SCNI $8.92
- SNPX $8.78
- Technical
- Relative Strength Index (RSI)
- SCNI 56.32
- SNPX 45.01
- Support Level
- SCNI $3.20
- SNPX $2.52
- Resistance Level
- SCNI $3.55
- SNPX $2.80
- Average True Range (ATR)
- SCNI 0.18
- SNPX 0.21
- MACD
- SCNI 0.03
- SNPX -0.01
- Stochastic Oscillator
- SCNI 51.72
- SNPX 33.32
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.